Omega-3 Fatty Acid Supplementation for Perinatal Depression: A Meta-Analysis

Instructions

Click the red REGISTER button to pay the $10 fee and take the posttest
Click here to return to the JCP CME article

Overview

When pregnant patients with a history of depression ask you about eating fish or using an omega-3 supplement, what do you tell them? Learn about research in the peripartum period in this journal CME activity.


Read the whole article at psychiatrist.com here: 
Omega-3 Fatty Acid Supplementation for Perinatal Depression: A Meta-Analysis

© Copyright 2020 Physicians Postgraduate Press, Inc.

Target Audience

Psychiatrists

Learning Objectives

Advise patients on the evidence for the use of omega-3 PUFA supplementation in the treatment of peripartum major depressive episodes

Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Activity opens: 
09/01/2020
Activity expires: 
10/31/2022
Cost:
$10.00
Rating: 
0

CME Background

Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.

CME Objective

After studying this article, you should be able to:

  • Advise patients on the evidence for the use of omega-3 PUFA supplementation in the treatment of peripartum major depressive episodes

Statement of Need and Purpose

Women ask their health care professionals for advice on the safety and effectiveness of MDD treatments during and after pregnancy. To facilitate decision-making, education for clinicians is needed on the evidence regarding perinatal use of omega-3 polyunsaturated fatty acids.

Release, Expiration, and Review Dates

This educational activity was published in September 2020 and is eligible for AMA PRA Category 1 Credit™ through October 31, 2022. The latest review of this material was August 2020.

Disclosure of off-label usage

The authors have determined that, to the best of their knowledge, omega-3 fatty acids are not approved by the US Food and Drug Administration for the treatment of peripartum depression.

Author contribution

Drs Mocking and Roos and Ms Steijn performed the literature search and data collection; Dr Mocking and Ms Steijn performed the analyses and drafted the figures; and all authors contributed to the study design, data interpretation, and writing of the manuscript.

Funding/support

This study was supported by a PhD scholarship awarded to Dr Mocking by the Academic Medical Center of the University of Amsterdam. Dr Ruhé is currently supported by a NWO/ZonMW VENI-Grant #016.126.059. Dr Bergink is supported by the Netherlands Organization for Scientific Research (NWO: VENI and clinical fellow) and the Blavatnik Womens Health Institute.

Role of the sponsor

The funding sources by no means influenced the design and conduct of the study; collection, management, analysis, and interpretation of the data; nor preparation, review, or approval of the manuscript; nor decision to submit the manuscript for submission.

Faculty Affiliation

Roel J. T. Mocking, MD, PhD*
Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Katja Steijn, BSc
Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Carolien Roos, MD, PhD
Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

Johanna Assies, MD, PhD
Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Veerle Bergink, MD, PhD
Department of Psychiatry and Department of Obstetrics, Icahn School of Medicine, New York, New York, and Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands

Henricus G. Ruhé, MD, PhD
Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, United Kingdom; Department of Psychiatry, Radboud University Medical Center, Nijmegen, The Netherlands; and Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands

Aart H. Schene, MD, PhD
Department of Psychiatry, Radboud University Medical Center, Nijmegen, The Netherlands, and Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands

‡These authors share senior authorship.

*Corresponding author: Roel J. T. Mocking, MD, PhD, Department of Psychiatry, Academic Medical Center, Meibergdreef 5, Amsterdam 1105 AZ, The Netherlands (R.J.Mocking@amsterdamumc.nl).

Financial Disclosure

All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Marlene P. Freeman, MD, Editor in Chief of The Journal of Clinical Psychiatry, has received research funding from JayMac and Sage; has been a member of the advisory boards for Otsuka, Alkermes, and Sunovion; has been a member of the Independent Data Safety and Monitoring Committee for Janssen; has been a member of the Steering Committee for Educational Activities for Medscape; and, as a Massachusetts General Hospital (MGH) employee, works with the MGH National Pregnancy Registry, which is sponsored by Teva, Alkermes, Otsuka, Actavis, and Sunovion, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. No member of the CME Institute staff reported any relevant personal financial relationships. Faculty financial disclosure appears at the end of the article.

Drs MockingRoosAssiesBerginkRuhé, and Schene and Ms Steijn have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article. All authors report no conflict of interests with regard to personal dietary preferences.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Price

Cost:
$10.00
Please login or register to take this activity.

Register for free on our site to participate in this and many other free CME courses.